Phio Pharmaceuticals Corp. announced on June 6, 2025, a strategic initiative aimed at heightening awareness of the potential applications of its comprehensive INTASYL siRNA portfolio. This portfolio includes approximately 30 compounds, demonstrating the breadth of the company's proprietary gene silencing technology designed to treat cancer by making the body's immune cells more effective.
In conjunction with this strategic focus, the company announced two key executive appointments. Robert Infarinato was named Vice President, Strategic Development, a role crucial for exploring and advancing the diverse applications of the INTASYL platform. Lisa Carson was appointed as the new Vice President, Finance and Administration, strengthening the company's financial leadership.
These appointments and the strategic initiative underscore Phio's commitment to maximizing the value of its innovative technology. By focusing on the broader portfolio, Phio aims to unlock new therapeutic avenues and potential partnerships, further solidifying its position in the immuno-oncology landscape.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.